The U.S. Food and Drug Administration will not approve a drug if there is more than a 2.5 percent chance that it doesn’t work—no matter the disease or how poor the prognosis. And in a recently published paper, Massachusetts Institute of Technology finance professor Andrew Lo took the FDA to task for not being more flexible. Jagpreet Chhatwal (Mass General) is quoted.
Trending News
Research Provides Clues to Spleen’s Role in Coronary Artery Disease
Genetic variants may drive visible changes in the spleen that contribute to heart disease
Patient Who Received Pig Kidney Becomes First To Progress to Human Kidney Transplant
Study shows xenotransplantation can serve as a bridge for patients with end-stage kidney disease
Pilots, Flight Attendants Have Greater Risk of Radiation-Related Cancer Death Than Other Professions
Findings support efforts to protect U.S. aircrews from cosmic radiation exposure